Trending Topic

abstract blue eye
8 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757636) and ShORe (OPT-302 with ranibizumab in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757610).2,3 These trials represent one of the largest phase […]

David Pelayes, EURETINA 2019 – Treatment approaches to DME

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Sep 16th 2019

David Pelayes (Professor of Ophthalmology, Medical Faculty Mannheim, Ruprecht-Karls-University, Heidelberg, Germany) discusses the current limitations with treatment approaches to DME and the evolving use of OCT-A to predict the response a patient have to DEM treatment.

Questions:
1. What recent advances in ophthalmology have had the biggest impact on your practice?
2. What are the major limitations of current treatment approaches to DME?
3. What factors are associated with a good response to anti-VEGF treatment?
4. How can OCT-A findings be used to predict the response to DME treatment?

Support: No funding was received in the production of this video.
Disclosures: Consultant to Topcon and VitrcQ

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup